SAIK ANDREW (EVP & Chief Financial Officer) received a stock award from INTERCEPT PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/31/2023ACC: 0001104659-23-008588
Officer· EVP & Chief Financial Officer
Since Jun 2021
+38.70K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
38.70K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+14.70K
Price / share
—
Trade value
—
% of position
26.1%
1/27/2023
56.29K→70.99K
Total
Net shares
+14.70K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/27/2023 | A · Award | +14.70K | — | — | 26.1% | 56.29K | 70.99K |
| Total | +14.70K | $0.00 | ||||||
Derivative Transactions1
Option to Purchase Common Stock
Direct
Converts to
Common Stock
24K shares
Shares
+24K
Strike price
18.40
Held after
24K
Exercisable
—
1/27/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Option to Purchase Common Stock Direct | Common Stock24K shares | 1/27/2023 | A · Award | +24K | 18.40 | — | 24K |